Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study Meeting Abstract
| Authors: | Bhave, M. A.; Jhaveri, K. L.; Kaufman, P. A.; Aftimos, P. G.; Lombard, J. M.; Sideras, K.; Im, S. A.; Ma, C. X.; Lee, K. T.; Kim, S. B.; Li, Y. J.; Yuen, E.; Estrem, S. T.; Nguyen, B.; Bacchion, F.; Ismail-Khan, R.; Beeram, M.; Sohn, J. |
| Abstract Title: | Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557400137 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.102 |
| Notes: | Meeting Abstract: 102 -- Source: Wos |
